Starton Therapeutics

Starton is an emerging clinical-stage biotechnology company transforming standard of care therapies with proprietary dermal delivery technology, so people with cancer can receive continuous treatment to live better, longer. Focused on continuous delivery: Starton’s proprietary dermal delivery technology can increase efficacy of approved drugs, make them more tolerable, and expand their potential use. We are advancing the following candidates in our continuous delivery platform: STAR-LLD: Transdermal and continuous subcutaneous formulations of lenalidomide for chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and other cancers. STAR-LLD has the potential to become the first immunomodulatory drug (IMiD) in CLL, and a best-in-class IMiD in MM. STAR-OLZ: Once-weekly transdermal olanzapine for chemotherapy induced nausea and vomiting (CINV).